In subsequent clinical trials with magrolimab (also an IgG4‐based CD47 antibody), the major yet manageable side effects in various cancer types were anaemia and infusion‐related reactions that did not lead to an MTD.16, 17, 18. This evidence concerns the gene CD47 and cancer.